NDAORALTABLET
Approved
Jun 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
STALEVO 100 (carbidopa, levodopa, and entacapone) by Orion Pharma is dopa decarboxylase inhibitors [moa]. Approved for aromatic amino acid decarboxylation inhibitor [epc]. First approved in 2003.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STALEVO 100 is a fixed-dose combination oral tablet containing carbidopa, levodopa, and entacapone, approved in 2003 for Parkinson's disease. It combines a DOPA decarboxylase inhibitor with levodopa (a dopamine precursor) and a catechol-O-methyltransferase inhibitor to enhance dopaminergic activity in the central nervous system. The triple combination extends levodopa efficacy and reduces motor fluctuations in advanced Parkinson's patients.
$0.229MPart D
LOE ApproachingStable
Mature product with approaching loss of exclusivity signals contraction phase; commercial teams should anticipate portfolio repositioning and generic transition planning.
Mechanism of Action
DOPA Decarboxylase Inhibitors
Pharmacologic Class:
Aromatic Amino Acid Decarboxylation Inhibitor
Indications (1)
Career Relevance
Zero linked job postings suggest minimal dedicated staffing growth or hiring momentum for STALEVO 100 specifically. Career development on this product centers on mature-stage brand management, government affairs (Part D/Medicare strategy), and transition planning for generic competition rather than innovation or growth roles.
Worked on STALEVO 100 at Orion Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.